CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-16 | Schuchart Aaron Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2017-04-21 | Quinn Anthony interim Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +24,000 | 24,000 | ||
| 2017-03-20 | York Charles N II Chief Financial Officer and VP | Grant or award · Employee Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2017-03-20 | TYLER JOSEPH E VP, Manufacturing | Grant or award · Employee Stock Option (right to buy) | +39,000 | 39,000 | ||
| 2017-03-20 | Rowlinson Scott W VP, Research | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2017-03-20 | Lowe David George CEO and President | Grant or award · Employee Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2017-02-15 | York Charles N II Chief Financial Officer and VP | Purchase | +2,000 | $4.28 | $9K | 12,828 |
| 2016-08-15 | York Charles N II Chief Financial Officer and VP | Purchase | +2,000 | $3.99 | $8K | 10,828 |
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Conversion | +2,010,924 | 2,010,924 | ||
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Purchase | +300,000 | $10.00 | $3.0M | 2,310,924 |
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Conversion · Series A Preferred Stock | −890,476 | 0 | ||
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Conversion · Series B Preferred Stock | −1,120,448 | 0 |
Page 19 of 19 · 372 trades